Ronald Blue Trust, Inc. Akero Therapeutics, Inc. Transaction History
Ronald Blue Trust, Inc.
- $7.98 Billion
- Q3 2024
A detailed history of Ronald Blue Trust, Inc. transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Ronald Blue Trust, Inc. holds 13 shares of AKRO stock, worth $365. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13Holding current value
$365% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AKRO
# of Institutions
190Shares Held
73.8MCall Options Held
241KPut Options Held
647K-
Wellington Management Group LLP Boston, MA7.9MShares$222 Million0.04% of portfolio
-
Janus Henderson Group PLC London, X07.08MShares$199 Million0.11% of portfolio
-
Rtw Investments, LP New York, NY5.92MShares$166 Million2.71% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$157 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$147 Million4.29% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.3B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...